臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

关于TAIR
	计画说明

浏览
	典藏机构
	作者
	题名
	日期
	统计图表
	机构即时统计
	学术趋势

消息
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

著作权
	出版社及期刊政策查询
	TAIR著作权会议记录

相关连结
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"jia horng kao"的相关文件

回到依作者浏览
依题名排序	依日期排序

显示项目 556-605 / 1180 (共24页)
<< < 7 8 9 10 11 12 13 14 15 16 > >>
每页显示[10|25|50]项目

机构	日期	题名	作者
臺大學術典藏	2021-09-04T05:17:11Z	Highlights	JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:17:11Z	Preface	JIA-HORNG KAO; Chen D.-S.
臺大學術典藏	2021-09-04T05:17:10Z	Highlights	JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:17:10Z	Hepatitis b virus–specific t cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation	Rivino L.; Le Bert N.; Gill U.S.; Kunasegaran K.; Cheng Y.; Tan D.Z.M.; Becht E.; Hansi N.K.; Foster G.R.; Su T.-H.; Tseng T.-C.; Lim S.G.; JIA-HORNG KAO; Newell E.W.; Kennedy P.T.F.; Bertoletti A.
臺大學術典藏	2021-09-04T05:17:10Z	Sofosbuvir-based Interferon-Free Direct Acting Antiviral Regimens for Heart Transplant Recipients with Chronic Hepatitis C Virus Infection	Liu C.-H.; Chen Y.-S.; Wang S.-S.; Liu C.-J.; Su T.-H.; Yang H.-C.; Hong C.-M.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:17:09Z	Prevention of mother-to-child transmission: the key of hepatitis B virus elimination	Lin C.-L.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:17:09Z	Highlights	JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:17:09Z	Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan	Liu C.-H.; Liu C.-J.; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:17:08Z	Highlights	JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:17:08Z	HCC risk in patients with HBV-related cirrhosis receiving nucleos(t)ide analogues therapy: Is HCC prevented or delayed?	Su T.-H.; Tseng T.-C.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:17:08Z	Highlights	JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:17:08Z	Distinct Relapse Rates and Risk Predictors after Discontinuing Tenofovir and Entecavir Therapy	Su T.-H.; Yang H.-C.; Tseng T.-C.; Liou J.-M.; Liu C.-H.; Chen C.-L.; Chen P.-J.; Chen D.-S.; Liu C.-J.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:17:07Z	Boceprevir-based triple therapy to rescue HCV genotype 1/HBV dually infected patients refractory to peginterferon plus ribavirin combination therapy in Taiwan	Hsieh M.-H.; Yeh M.-L.; Su T.-H.; Liu T.-W.; Huang C.-F.; Huang C.-I.; Wang S.-C.; Huang J.-F.; Dai C.-Y.; JIA-HORNG KAO; Chuang W.-L.; Chen P.-J.; Liu C.-J.; Yu M.-L.
臺大學術典藏	2021-09-04T05:17:07Z	Fibrosis-4 index predicts cirrhosis risk and liver-related mortality in 2075 patients with chronic HBV infection	Tseng T.-C.; Liu C.-J.; Su T.-H.; Yang W.-T.; Chen C.-L.; Yang H.-C.; Kuo S.F.-T.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:17:06Z	The effect of interferon-free regimens on health-related quality of life in East Asian patients with chronic hepatitis C	Younossi Z.M.; Stepanova M.; Henry L.; Han K.-H.; Ahn S.H.; Lim Y.-S.; Chuang W.-L.; JIA-HORNG KAO; Kinh N.; Lai C.L.; Yuen M.-F.; Chan H.L.-Y.; Lai W.
臺大學術典藏	2021-09-04T05:17:06Z	Highlights	JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:17:06Z	Generic velpatasvir plus sofosbuvir for hepatitis C virus infection in patients with or without human immunodeficiency virus coinfection	Liu C.-H.; Sun H.-Y.; Liu C.-J.; Sheng W.-H.; Hsieh S.-M.; Lo Y.-C.; Liu W.-C.; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Hung C.-C.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:17:05Z	Acoustic radiation force impulse US imaging: Liver stiffness in patients with chronic hepatitis B with and without antiviral therapy	Su T.-H.; Liao C.-H.; Liu C.-H.; Huang K.-W.; Tseng T.-C.; Yang H.-C.; Liu C.-J.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:17:05Z	Phase IV randomized clinical study: Peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B	Hsu C.-W.; Su W.-W.; Lee C.-M.; Peng C.-Y.; Chuang W.-L.; JIA-HORNG KAO; Chu H.-C.; Huang Y.-H.; Chien R.-N.; Liaw Y.-F.
臺大學術典藏	2021-09-04T05:17:05Z	Highlights	JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:17:05Z	Review article: the prevention of hepatitis B-related hepatocellular carcinoma	Lin C.-L.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:17:04Z	Significance of definitions of relapse after discontinuation of oral antivirals in HBeAg-negative chronic hepatitis B	Papatheodoridis G.V.; Manolakopoulos S.; Su T.-H.; Siakavellas S.; Liu C.-J.; Kourikou A.; Yang H.-C.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:17:04Z	Twelve-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin for non-cirrhotic HCV genotype 1 patients: A phase 2 study	JIA-HORNG KAO; Yu M.-L.; Chen C.-Y.; Peng C.-Y.; Chen M.-Y.; Tang H.; Chen Q.; Wu J.J.
臺大學術典藏	2021-09-04T05:17:04Z	Highlights	JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:17:03Z	Hepatitis B: From control to cure	JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:17:03Z	Quantification of serum hepatitis B core antibody to predict off-entecavir relapse in patients with chronic hepatitis B	Tseng C.-H.; Hsu Y.-C.; Chang C.-Y.; Tseng T.-C.; Wu M.-S.; Lin J.-T.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:17:03Z	Highlights	JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:17:01Z	Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection	Reau N.; Kwo P.Y.; Rhee S.; Brown R.S.; Jr.; Agarwal K.; Angus P.; Gane E.; JIA-HORNG KAO; Mantry P.S.; Mutimer D.; Reddy K.R.; Tran T.T.; Hu Y.B.; Gulati A.; Krishnan P.; Dumas E.O.; Porcalla A.; Shulman N.S.; Liu W.; Samanta S.; Trinh R.; Forns X.
臺大學術典藏	2021-09-04T05:17:01Z	Highlights	JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:17:01Z	Highlights	JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:17:00Z	Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study	Liu C.-H.; Huang Y.-J.; Yang S.-S.; Chang C.-H.; Yang S.-S.; Sun H.-Y.; Liu C.-J.; Liu W.-C.; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Hung C.-C.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:17:00Z	Sofosbuvir and ledipasvir are associated with high sustained virologic response and improvement of health-related quality of life in East Asian patients with hepatitis C virus infection	Younossi Z.M.; Stepanova M.; Henry L.; Han K.-H.; Ahn S.H.; Lim Y.-S.; Chuang W.-L.; JIA-HORNG KAO; Nguyen K.V.; Lai C.L.; Chan H.L.-Y.; Wei L.
臺大學術典藏	2021-09-04T05:17:00Z	One-year weight management lowers lipopolysaccharide-binding protein and its implication in metainflammation and liver fibrosis	Nien H.-C.; Sheu J.-C.; Chi Y.-C.; Chen C.-L.; JIA-HORNG KAO; Yang W.-S.
臺大學術典藏	2021-09-04T05:16:59Z	Serine/threonine protein phosphatase 5 is a potential therapeutic target in cholangiocarcinoma	Hu M.-H.; Huang T.-T.; Chao T.-I.; Chen L.-J.; Chen Y.-L.; Tsai M.-H.; Liu C.-Y.; JIA-HORNG KAO; Chen K.-F.
臺大學術典藏	2021-09-04T05:16:59Z	Highlights	JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:59Z	Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan	Liu C.-H.; Yu M.-L.; Peng C.-Y.; Hsieh T.-Y.; Huang Y.-H.; Su W.-W.; Cheng P.-N.; Lin C.-L.; Lo C.-C.; Chen C.-Y.; Chen J.-J.; Ma Q.; Brooks-Rooney C.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:58Z	A novel spontaneous hepatocellular carcinoma mouse model for studying T-cell exhaustion in the tumor microenvironment	Liu Y.-T.; Tseng T.-C.; Soong R.-S.; Peng C.-Y.; Cheng Y.-H.; Huang S.-F.; Chuang T.-H.; JIA-HORNG KAO; Huang L.-R.
臺大學術典藏	2021-09-04T05:16:58Z	Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan	Liu C.-H.; Liu C.-J.; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:58Z	Sarcopenia and chronic liver diseases	Hsu C.-S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:57Z	Quantification of HBV core antibodies may help revisit infectious occult hepatitis B virus	Yang H.-C.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:57Z	Editorial: comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting anti-viral agents in chronic hepatitis C – authors’ reply	Liu C.-H.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:57Z	Taiwan consensus statement on the management of chronic hepatitis B	Chien R.-N.; JIA-HORNG KAO; Peng C.-Y.; Chen C.-H.; Liu C.-J.; Huang Y.-H.; Hu T.-H.; Yang H.-I.; Lu S.-N.; Ni Y.-H.; Chuang W.-L.; Lee C.-M.; Wu J.-C.; Chen P.-J.; Liaw Y.-F.
臺大學術典藏	2021-09-04T05:16:56Z	Genetic variation in FCER1A predicts peginterferon alfa-2a-induced hepatitis B surface antigen clearance in East Asian patients with chronic hepatitis B	Wei L.; Pavlovic V.; Bansal A.T.; Chen X.; Foster G.R.; He H.; JIA-HORNG KAO; Lampertico P.; Liaw Y.-F.; Motoc A.; Papatheodoridis G.V.; Piratvisuth T.; Plesniak R.; Wat C.
臺大學術典藏	2021-09-04T05:16:56Z	Peginterferon alfa-2a (40 kD) stopping rules in chronic hepatitis B: A systematic review and meta-analysis of individual participant data	Pavlovic V.; Yang L.; Chan H.L.-Y.; Hou J.; Janssen H.L.; JIA-HORNG KAO; Lampertico P.; Peng C.-Y.; Piratvisuth T.; Thompson A.J.; Wedemeyer H.; Wei L.; Wat C.
臺大學術典藏	2021-09-04T05:16:56Z	Clinical Manifestations and Outcomes of Patients with Sarcomatoid Hepatocellular Carcinoma	Liao S.-H.; Su T.-H.; Jeng Y.-M.; Liang P.-C.; Chen D.-S.; Chen C.-H.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:56Z	Editorial: nephrotoxicity and oral anti-viral therapy for HBV-facts or fiction?	Liu C.-H.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:55Z	Large and middle hepatitis B surface antigen: The lower the better?	Lin H.-H.; Tseng T.-C.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:55Z	Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions	Yu M.-L.; Hung C.-H.; Huang Y.-H.; Peng C.-Y.; Lin C.-Y.; Cheng P.-N.; Chien R.-N.; Hsu S.-J.; Liu C.-H.; Huang C.-F.; Su C.-W.; Huang J.-F.; Liu C.-J.; JIA-HORNG KAO; Chuang W.-L.; Chen P.-J.; Chen D.-S.
臺大學術典藏	2021-09-04T05:16:55Z	Profile and value of FIB-4 in patients with dual chronic hepatitis C and B	Liu C.-J.; Tseng T.-C.; Yang W.-T.; Su T.-H.; Yang H.-C.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:54Z	Early antiviral therapy reduces the risk of lymphoma in patients with chronic hepatitis C infection	Su T.-H.; Liu C.-J.; Tseng T.-C.; Chou S.-W.; Liu C.-H.; Yang H.-C.; Wu S.-J.; Chen P.-J.; Chen D.-S.; Chen C.-L.; JIA-HORNG KAO

显示项目 556-605 / 1180 (共24页)
<< < 7 8 9 10 11 12 13 14 15 16 > >>
每页显示[10|25|50]项目

	English \| 正體中文 \| 简体中文 \| 总笔数 :0
	造访人次 : 51503144 在线人数 : 864 教育部委托研究计画计画执行:国立台湾大学图书馆